Purisys is a global leader in custom synthesis of active pharmaceutical ingredients. We support pharma & biotech companies with APIs, reference standards, controlled substances, cannabinoids, psychedelics, and cGMP clinical & niche commercial CDMO services. Formed as a spin-off from Noramco in 2019, Purisys began manufacturing in 1979 as part of Johnson & Johnson.

WORLD LEADER IN PHARMACEUTICAL CANNABINOIDS, PSYCHEDELICS & REFERENCE STANDARDS 
Purisys produces 50+ major and minor cannabinoids, as well as degradants, metabolites & analytical standards to support our customers in this growing field. In addition, we have DEA licenses for several Psychedelic basic classes and have produced GMP psilocybin and Psilocin supporting customers’ R&D programs. We have multiple DMFs, including Dronabinol (#20682), CBD (#33223), Nabilone (#35408), and have produced other cannabinoids used worldwide in IND/IMPD/NDA/ANDA filings. 

CUSTOM API and DRUG DEVELOPMENT & MANUFACTURING (CDMO) SERVICES FOR PHARMA & BIOTECH
For clients seeking preclinical-to-commercial APIs, we provide comprehensive development, analytical and manufacturing services - including full-service clinical-to-commercial small volume & orphan drug commercial API synthesis in our FDA-inspected GMP manufacturing suites. Our custom synthesis projects include difficult-to-manufacture APIs (controlled substances, injectable-grade APIs, HPAPIs and environmentally sensitive APIs).

IN-STOCK REFERENCE STANDARDS AND CUSTOM SYNTHESIS SERVICES
Purisys stocks 250+ reference standards with structural elucidation and comprehensive analytical data. We ship reference standards to 30+ countries on 6 continents.

CAPABILITIES:
•	Cannabinoid and psychedelic APIs suitable for registered pharma research to treat, cure, or prevent disease
•	In-stock standards; custom synthesis & qualification
•	Excipient compatibility & formulation & solid state
•	cGMP manufacturing
•	HPAPI & labile molecule development 
•	Method development

Purisys

Org chart

Teams

Offices